BCM
KDNY

Bridgeway Capital Management’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Bridgeway Capital Management’s Portfolio KDNY Stock Details KDNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-6,520
Closed -$75K – 1372
2020
Q2 		$75K Sell
6,520
-4,120
-39% -$56.8K ﹤0.01% 1261
2020
Q1 		$146K Sell
10,640
-61,720
-85% -$730K ﹤0.01% 1129
2019
Q4 		$427K Buy
72,360
+2,720
+4% +$14.8K 0.01% 1042
2019
Q3 		$369K Hold
69,640
– – 0.01% 1048
2019
Q2 		$536K Hold
69,640
– – 0.01% 955
2019
Q1 		$1.39M Buy
69,640
+47,820
+219% +$834K 0.02% 649
2018
Q4 		$288K Buy
+21,820
New +$436K ﹤0.01% 1139

Other funds holding KDNY

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

Bridgeway Capital Management's KDNY Position: Q3 2020 in Review

Bridgeway Capital Management sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q3 2020, closing a stake of 6,520 shares — an estimated $75K sold.

Bridgeway Capital Management first reported a position in KDNY in Q4 2018 and held it in 7 quarters. The position peaked at $1.39M in Q1 2019. 70 funds tracked by Wall St. Rank hold KDNY as of Q3 2020.

  • Bridgeway Capital Management reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q3 2020 after selling out during the quarter.
  • Bridgeway Capital Management sold 6,520 Chinook Therapeutics, Inc. Common Stock shares in Q3 2020, an estimated $75K.
  • Bridgeway Capital Management first reported a position in Chinook Therapeutics, Inc. Common Stock in Q4 2018 and held it in 7 quarters.
  • Bridgeway Capital Management's Chinook Therapeutics, Inc. Common Stock position peaked at $1.39M in Q1 2019.
  • 70 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q3 2020.

Based on Bridgeway Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.